EXEL - Exelixis sees Q4 revenue revenue of $415M and issues FY23 guidance
- Exelixis ( NASDAQ: EXEL ) expects revenue for the fourth quarter to be $415M vs. consensus at $415.86M. For 2022, the company sees revenue of $1.6B vs. consensus at $1.6B.
- The company also said it expects 2023 revenue of $1.775B-$1.875B vs. consensus at $1.83B.
- Cabozantinib franchise achieves ~$1.4B in preliminary U.S. net product revenues for full year 2022, including ~$375M for fourth quarter 2022.
- Full year 2023 net product revenues guidance of $1,575 million - $1,675 million.
- Corporate priorities for 2023 include readout of Phase 3 trials for cabozantinib, expansion of the Phase 3 program for zanzalintinib, progression of XB002 into full development, and advancement of Exelixis’ earlier stage pipeline.
For further details see:
Exelixis sees Q4 revenue revenue of $415M and issues FY23 guidance